Sevoflurane-sulfobutylether-β-cyclodextrin complex: Preparation, characterization, cellular toxicity, molecular modeling and blood-brain barrier transport studies

Molecules

Volumn 20, Issue 6, 2015, Pages 10264-10279

  Shityakov, Sergey ^a   Puskás, István ^b   Pápai, Katalin ^c   Salvador, Ellaine ^a   Roewer, Norbert ^a,c   Förster, Carola ^a   Broscheit, Jens Albert ^a,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b CycloLab Cyclodextrin Research & Development Laboratory Ltd   (Hungary)

^c Sapiotec GmbH   (Germany)

Author keywords

Blood brain barrier; Cyclodextrin formulations; Molecular docking; Molecular liphophilicity potential; Primary microvascular endothelial cells; Sevoflurane; Sulfobutylether cyclodextrin

Indexed keywords

BETA CYCLODEXTRIN DERIVATIVE; DELAYED RELEASE FORMULATION; ETHER DERIVATIVE; INHALATION ANESTHETIC AGENT; PROPRANOLOL; SBE4-BETA-CYCLODEXTRIN; SEVOFLURANE;

ANIMAL; BLOOD BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CELL SURVIVAL; CHEMISTRY; CYTOLOGY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; DRUG FORMULATION; ENDOTHELIUM CELL; METABOLISM; MOLECULAR DOCKING; MOUSE; PRIMARY CELL CULTURE; VASCULARIZATION;

ANESTHETICS, INHALATION; ANIMALS; BETA-CYCLODEXTRINS; BLOOD-BRAIN BARRIER; BRAIN; CAPILLARY PERMEABILITY; CELL SURVIVAL; DELAYED-ACTION PREPARATIONS; DRUG COMPOUNDING; ENDOTHELIAL CELLS; METHYL ETHERS; MICE; MOLECULAR DOCKING SIMULATION; PRIMARY CELL CULTURE; PROPRANOLOL;

EID: 84938403667     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules200610264     Document Type: Article

References (40)

1. Wallin, R.F.; Regan, B.M.; Napoli, M.D.; Stern, I.J. Sevoflurane: A new inhalational anesthetic agent. Anesth. Analg. 1975, 54, 758-766.
2. Ebert, T.J.; Schmid, P.G., III. Inhalation Anesthesia, Chapter 15. In Clinical Anesthesia, 4th ed.; Barash, P.G., Cullen, B.F., Stoelting, R.K., Eds.; Lippincott Williams& Wilkins: Philadelphia, PA, USA, 2001; pp. 377-387.
3. Jin, L.; Baillie, T.A.; Davis, M.R.; Kharasch, E.D. Nephrotoxicity of sevoflurane compound A [fluoromethyl-2,2-difluoro-1-(trifluoromethyl)vinyl ether] in rats: Evidence for glutathione and cysteine conjugate formation and the role of renal cysteine conjugate beta-lyase. Biochem. Biophys. Res. Commun. 1995, 210, 498-506.
4. Martin, J.L.; Kandel, L.; Laster, M.J.; Kerschmann, R.L.; Eger, E.I., II. Studies of the mechanism of nephrotoxicity of compound A in rats. J. Anaesth. 1997, 11, 32-37.
5. Ma, D.Q.; Rajewski, R.A.; Stella, V.J. New injectable melphan formulations utilizing (SBE)7m-b-CD or HP-b-CD. Int. J. Pharm. 1999, 189, 227-234.
6. Loftsson, T.; Brewster, M.E. Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J. Pharm. Sci. 1996, 85, 1017-1025.
7. Jain, A.S.; Date, A.A.; Pissurlenkar, R.R.; Coutinho, E.C.; Nagarsenker, M.S. Sulfobutyl ether(7) beta-cyclodextrin (SBE(7) beta-CD) carbamazepine complex: Preparation, characterization, molecular modeling, and evaluation of in vivo anti-epileptic activity. AAPS PharmSciTech 2011, 12, 1163-1175.
8. Nagase, Y.; Hirata, M.; Arima, H.; Tajiri, S.; Nishimoto, Y.; Hirayama, F.; Irie, T.; Uekama, K. Protective effect of sulfobutyl ether beta-cyclodextrin on DY-9760e-induced hemolysis in vitro. J. Pharm. Sci. 2002, 91, 2382-2389.
9. Tötterman, A.M.; Schipper, N.G.; Thompson, D.O.; Mannermaa, J.P. Intestinal safety of water-soluble beta-cyclodextrins in paediatric oral solutions of spironolactone: Effects on human intestinal epithelial Caco-2 cells. J. Pharm. Pharmacol. 1997, 49, 43-48.
10. Irie, T.; Uekama, K. Pharmaceutical applications of cyclodextrins. III. Toxicological issues and safety evaluation. J. Pharm. Sci. 1997, 86, 147-162.
11. Kiss, T.; Fenyvesi, F.; Bácskay, I.; Váradi, J.; Fenyvesi, E.; Iványi, R.; Szente, L.; Tósaki, A.; Vecsernyés, M. Evaluation of the cytotoxicity of beta-cyclodextrin derivatives: Evidence for the role of cholesterol extraction. Eur. J. Pharm. Sci. 2010, 40, 376-380.
12. McIntosh, M.P.; Schwarting, N.; Rajewski, R.A. In vitro and in vivo evaluation of a sulfobutyl ether beta-cyclodextrin enabled etomidate formulation. J. Pharm. Sci. 2004, 93, 2585-2594.
13. Babu, M.K.; Godiwala, T.N. Toward the development of an injectable dosage form of propofol: Preparation and evaluation of propofol-sulfobutyl ether 7-beta-cyclodextrin complex. Pharm. Dev. Technol. 2004, 9, 265-275.
14. McIntosh, M.P.; Narita, H.; Kameyama, Y.; Rajewski, R.A.; Goto, H. Evaluation of mean arterial blood pressure, heart rate, and sympathetic nerve activity in rabbits after administration of two formulations of etomidate. Vet. Anaesth. Analg. 2007, 34, 149-156.
15. Goodchild, C.S.; Serrao, J.M.; Kolosov, A.; Boyd, B.J. Alphaxalone Reformulated: A Water-Soluble Intravenous Anesthetic Preparation in Sulfobutyl-Ether-beta-Cyclodextrin. Anesth. Analg. 2014, doi:10.1213/ANE.0000000000000559.
16. Ribeiro, A.; Figueiras, A.; Santos, D.; Veiga, F. Preparation and solid-state characterization of inclusion complexes formed between miconazole and methyl-beta-cyclodextrin. AAPS PharmSciTech 2008, 9, 1102-1109.
17. Naidu, N.B.; Chowdary, K.P.; Murthy, K.V.; Satyanarayana, V.; Hayman, A.R.; Becket, G. Physicochemical characterization and dissolution properties of meloxicam-cyclodextrin binary systems. J. Pharm. Biomed. Anal. 2004, 35, 75-86.
18. Pomponio, R.; Gotti, R.; Fiori, J.; Cavrini, V.; Mura, P.; Cirri, M.; Maestrelli, F. Photostability studies on nicardipine-cyclodextrin complexes by capillary electrophoresis. J. Pharm. Biomed. Anal. 2004, 35, 267-275.
19. Hong, J.; Shah, J.C.; Mcgonagle, M.D. Effect of cyclodextrin derivation and amorphous state of complex on accelerated degradation of ziprasidone. J. Pharm. Sci. 2011, 100, 2703-2716.
20. Fischer, K. Neues Verfahren zur maßanalytischen Bestimmung des Wassergehaltes von Flüssigkeiten und festen Körpern. Angew. Chem. 1935, 48, 394-396.
21. Nitzschke, R.; Wilgusch, J.; Kersten, J.F.; Trepte, C.J.; Haas, S.A.; Reuter, D.A.; Goetz, A.E.; Goepfert, M.S. Changes in sevoflurane plasma concentration with delivery through the oxygenator during on-pump cardiac surgery. Br. J. Anaesth. 2013, 110, 957-965.
22. Nagare, N.; Damre, A.; Singh, K.S.; Mallurwar, S.R.; Iyer, S.; Naik, A.; Chintamaneni, M. Determination of site of absorption of propranolol in rat gut using in situ single-pass intestinal perfusion. Indian J. Pharm. Sci. 2010, 72, 625-629.
23. Imam, S.S.; Ahad, A.; Agil, M.; Sultana, Y.; Ali, A. A validated RP-HPLC method for simultaneous determination of propranolol and valsartan in bulk drug and gel formulation. J. Pharm. Bioallied Sci. 2013, 5, 61-65.
24. Dutta, H.; Sengupta, M.; Pal, D.K.; De, A.U.; Sengupta, C. Effect of propranolol hydrochloride on blood cell lipids in relation to partition coefficient and biological activity. Indian J. Biochem. Biophys. 1993, 30, 128-132.
25. Walgren, R.A.; Walle, T. The influence of plasma binding on absorption/exsorption in the Caco-2 model of human intestinal absorption. J. Pharm. Pharmacol. 1999, 51, 1037-1040.
26. Heinlein, A.; Metzger, M.; Walles, H.; Buettner, A. Transport of hop aroma compounds across Caco-2 monolayers. Food Funct. 2014, 5, 2719-2730.
27. Hidalgo, I.; Li, J. The evolving role of the Caco-2 cell model to estimate intestinal absorption potential and elucidate transport mechanisms. In The Process of New Drug Discovery and Development, 2nd ed.; Smith, C.G., O'Donnell, J.T., Eds.; Informa Healthcare USA, Inc.: New York, NY, USA, 2006; pp. 161-186.
28. Biganzoli, E.; Cavenaghi, L.A.; Rossi, R.; Brunati, M.C.; Nolli, M.L. Use of a Caco-2 cell culture model for the characterization of intestinal absorption of antibiotics. Il Farmaco 1999, 54, 594-599.
29. Frijlink, H.W.; Franssen, E.J.; Eissens, A.C.; Oosting, R.; Lerk, C.F.; Meijer, D.K. The effects of cyclodextrins on the disposition of intravenously injected drugs in the rat. Pharm. Res. 1991, 8, 380-384.
30. Blach, P.; Landy, D.; Fourmentin, S.; Surpateanu, G.; Bricout, H.; Ponchel, A.; Hapiot, F.; Monflier, E. Sulfobutyl ether-beta-cyclodextrins: Promising supramolecular carriers for aqueous organometallic catalysis. Adv. Synth. Catal. 2005, 347, 1301-1307.
31. Jug, M.; Mennini, N.; Melani, F.; Maestrelli, F.; Mura, P. Phase solubility,1 H NMR and molecular modelling studies of bupivacaine hydrochloride complexation with different cyclodextrin derivates. Chem. Phys. Lett. 2010, 500, 347-354.
32. Shityakov, S.; Broscheit, J.; Förster, C. alpha-Cyclodextrin dimer complexes of dopamine and levodopa derivatives to assess drug delivery to the central nervous system: ADME and molecular docking studies. Int. J. Nanomed. 2012, 7, 3211-3219.
33. Shityakov, S.; Forster, C. In silico predictive model to determine vector-mediated transport properties for the blood-brain barrier choline transporter. Adv. Appl. Bioinform. Chem. 2014, 7, 23-36.
34. Nurisso, A.J.; Bravo, J.; Carrupt, P.A.; Daina, A. Molecular docking using the molecular lipophilicity potential as hydrophobic descriptor: Impact on GOLD docking performance. J. Chem. Inf. Model. 2012, 52, 1319-1327.
35. Gasteiger, J.; Marsili, M. Iterative Partial Equalization of Orbital Electronegativity-A Rapid Access to Atomic Charges. Tetrahedron 1980, 36, 3219-3228.
36. Goodsell, D.S.; Morris, G.M.; Olson, A.J. Automated docking of flexible ligands: Applications of AutoDock. J. Mol. Recognit. 1996, 9, 1-5.
37. Seeliger, D.; de Groot, B.L. Ligand docking and binding site analysis with PyMOL and Autodock/Vina. J. Comput. Aided Mol. Des. 2010, 24, 417-422.
38. Shityakov, S.; Sohajda, T.; Puskás, I.; Roewer, N.; Förster, C.; Broscheit, J.A. Ionization states, cellular toxicity and molecular modeling studies of midazolam complexed with trimethyl-beta-cyclodextrin. Molecules 2014, 19, 16861-16876.
39. Gaillard, P.; Carrupt, P.A.; Testa, B.; Boudon, A. Molecular lipophilicity potential, a tool in 3D QSAR: Method and applications. J. Comput. Aided Mol. Des. 1994, 8, 83-96.
40. Oberhauser, N.; Nurisso, A.; Carrupt, P.A. MLP Tools: A PyMOL plugin for using the molecular lipophilicity potential in computer-aided drug design. J. Comput. Aided. Mol. Des. 2014, 28, 587-596.